|
AP2007004244A0
(en)
|
2005-05-10 |
2007-12-31 |
Intermune Inc |
Method of modulating stress-activated protein kinase system
|
|
RS55630B1
(sr)
*
|
2005-12-21 |
2017-06-30 |
Janssen Pharmaceutica Nv |
Triazolopiridazini kao modulatori tirozin kinaze
|
|
CA2651979A1
(en)
*
|
2006-05-30 |
2007-12-06 |
Pfizer Products Inc. |
Triazolopyridazine derivatives
|
|
JP5415942B2
(ja)
|
2006-06-22 |
2014-02-12 |
プラナ バイオテクノロジー リミティッド |
処置の方法およびその処置に有用な薬剤
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20121506A1
(es)
*
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
WO2008011045A2
(en)
*
|
2006-07-18 |
2008-01-24 |
Cytovia, Inc. |
3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
|
|
US7683060B2
(en)
|
2006-08-07 |
2010-03-23 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
NZ575548A
(en)
*
|
2006-09-18 |
2011-09-30 |
Vertex Pharma |
Heterocyclic inhibitors of c-Met and uses thereof
|
|
GEP20125658B
(en)
|
2006-11-22 |
2012-10-10 |
Incyte Corp |
Imidazotriazines and imidazo pyrimidines as kinase inhibitors
|
|
US8536168B2
(en)
*
|
2007-03-15 |
2013-09-17 |
Novartis Ag |
Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
|
|
US20090156594A1
(en)
*
|
2007-05-21 |
2009-06-18 |
Sgx Pharmaceuticals, Inc. |
Heterocyclic kinase modulators
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
WO2009005675A1
(en)
*
|
2007-06-28 |
2009-01-08 |
Abbott Laboratories |
Novel triazolopyridazines
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
FR2929613B1
(fr)
*
|
2008-04-02 |
2010-12-31 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
|
|
PA8792501A1
(es)
*
|
2007-08-09 |
2009-04-23 |
Sanofi Aventis |
Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
|
|
FR2919870B1
(fr)
*
|
2007-08-09 |
2014-05-16 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
|
|
DK2193133T3
(en)
|
2007-09-27 |
2015-10-05 |
Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii |
IMIDAZOLOTHIADIAZOLES USED AS PROTEINKINASE INHIBITORS
|
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
PE20091468A1
(es)
|
2008-02-28 |
2009-10-22 |
Novartis Ag |
DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
|
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
SI2300455T1
(sl)
|
2008-05-21 |
2017-12-29 |
Incyte Holdings Corporation |
Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
|
|
EP2296653B1
(en)
|
2008-06-03 |
2016-01-27 |
Intermune, Inc. |
Compounds and methods for treating inflammatory and fibrotic disorders
|
|
DE102008028905A1
(de)
*
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
UY32049A
(es)
|
2008-08-14 |
2010-03-26 |
Takeda Pharmaceutical |
Inhibidores de cmet
|
|
DE102008038220A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Oxadiazolderivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
DE102008038222A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Indazol-5-carbonsäurehydrazid-derivate
|
|
MX2011005250A
(es)
*
|
2008-11-19 |
2011-07-29 |
Vertex Pharma |
Inhibidores de triazolotiadiazol de cinasa de proteina c-met.
|
|
EP2356116A1
(en)
|
2008-11-20 |
2011-08-17 |
OSI Pharmaceuticals, Inc. |
Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
|
|
PA8851101A1
(es)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
EA019320B1
(ru)
|
2008-12-22 |
2014-02-28 |
Мерк Патент Гмбх |
Новые полиморфные формы дигидрофосфата 6-(1-метил-1h-пиразол-4-ил)-2-{3-[5-(2-морфолин-4-илэтокси)пиримидин-2-ил]бензил}-2h-пиридазин-3-она и способы их получения
|
|
DE102008062825A1
(de)
*
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
FR2941950B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941949B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941951B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941952B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
WO2010092371A1
(en)
|
2009-02-10 |
2010-08-19 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
|
JP2012519731A
(ja)
*
|
2009-03-09 |
2012-08-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ニコチン受容体およびｇａｂａａ受容体のアロステリックモジュレーターとしての置換複素環およびそれらの使用
|
|
AU2010231162B2
(en)
|
2009-04-02 |
2014-12-11 |
Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii |
Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives
|
|
UA106082C2
(uk)
*
|
2009-05-28 |
2014-07-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
АМІНОПІРАЗОЛ ТРИАЗОЛОТІАДІАЗОЛЬНІ ІНГІБІТОРИ ПРОТЕЇНКІНАЗИ c-МЕТ
|
|
WO2010138673A1
(en)
*
|
2009-05-28 |
2010-12-02 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of c-met protein kinase
|
|
US8269013B2
(en)
|
2009-05-28 |
2012-09-18 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrazole inhibitors of c-Met protein kinase
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
|
IN2012DN01453A
(enExample)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
|
PT3511330T
(pt)
*
|
2009-12-31 |
2020-12-24 |
Hutchison Medipharma Ltd |
Intermediário sintético útil na preparação de inibidores de triazolopiridina c-met
|
|
MX2012008898A
(es)
|
2010-02-03 |
2012-11-06 |
Incyte Corp |
Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
|
|
US20130072495A1
(en)
|
2010-05-14 |
2013-03-21 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
JP5960688B2
(ja)
|
2010-05-17 |
2016-08-02 |
インコゼン セラピューティクス プライベート リミテッド |
プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
|
|
JP2013527195A
(ja)
*
|
2010-05-27 |
2013-06-27 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｃ−Ｍｅｔプロテインキナーゼのアミノピラゾールトリアゾロチアジアゾールインヒビター
|
|
EP2588107A1
(en)
|
2010-07-01 |
2013-05-08 |
Takeda Pharmaceutical Company Limited |
COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
|
|
AR085183A1
(es)
*
|
2010-07-30 |
2013-09-18 |
Lilly Co Eli |
Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
|
|
JP2014513724A
(ja)
|
2011-05-16 |
2014-06-05 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
融合二環キナーゼ阻害剤
|
|
AU2012335220B2
(en)
|
2011-11-11 |
2017-06-01 |
Pfizer Inc. |
2-thiopyrimidinones
|
|
WO2013134562A1
(en)
|
2012-03-09 |
2013-09-12 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
CN104302640A
(zh)
|
2012-03-16 |
2015-01-21 |
埃克希金医药品有限公司 |
3,5-二氨基吡唑激酶抑制剂
|
|
CN104321322A
(zh)
|
2012-03-30 |
2015-01-28 |
理森制药股份公司 |
作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
|
|
AR092742A1
(es)
|
2012-10-02 |
2015-04-29 |
Intermune Inc |
Piridinonas antifibroticas
|
|
MX376108B
(es)
|
2012-12-20 |
2025-03-07 |
Tempest Therapeutics Inc |
Compuestos de triazolona y usos de los mismos.
|
|
AU2014315151A1
(en)
|
2013-09-06 |
2016-03-03 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
AU2013402175B2
(en)
|
2013-09-30 |
2017-09-07 |
Handok Inc. |
Novel triazolopyrazine derivative and use thereof
|
|
GB201321745D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
RU2692485C2
(ru)
|
2014-04-02 |
2019-06-25 |
Интермьюн, Инк. |
Противофиброзные пиридиноны
|
|
EP3229836B1
(en)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
|
MY191736A
(en)
|
2014-12-23 |
2022-07-13 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
WO2016161125A1
(en)
|
2015-03-31 |
2016-10-06 |
University Of Vermont And State Agricultural College |
Methods for treating cryptosporidiosis using triazolopyridazines
|
|
SG11201708407TA
(en)
|
2015-05-05 |
2017-11-29 |
Pfizer |
2-thiopyrimidinones
|
|
BR112017028137B1
(pt)
*
|
2015-06-25 |
2023-04-04 |
Taiho Pharmaceutical Co., Ltd |
Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste
|
|
HUE057041T2
(hu)
|
2015-07-06 |
2022-04-28 |
Alkermes Inc |
Hiszton deacetiláz hetero-halogén gátlói
|
|
WO2017007755A1
(en)
|
2015-07-06 |
2017-01-12 |
Rodin Therapeutics, Inc. |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
|
|
US10392347B2
(en)
|
2015-10-14 |
2019-08-27 |
Bristol-Myers Squibb Company |
2,4-dihydroxy-nicotinamides as APJ agonists
|
|
AR106948A1
(es)
|
2015-12-04 |
2018-03-07 |
Bristol Myers Squibb Co |
Agonistas del receptor de apelina y método de uso
|
|
EP3390400B1
(en)
|
2015-12-16 |
2021-01-20 |
Bristol-Myers Squibb Company |
Heteroarylhydroxypyrimidinones as agonists of the apj receptor
|
|
MY189454A
(en)
|
2016-03-24 |
2022-02-14 |
Bristol Myers Squibb Co |
6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
|
|
GR1009565B
(el)
*
|
2016-07-14 |
2019-08-06 |
Galenica Α.Ε. |
Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων
|
|
HRP20220223T1
(hr)
|
2017-01-11 |
2022-04-29 |
Alkermes, Inc. |
Biciklički inhibitori histon deacetilaze
|
|
DK3583943T3
(da)
|
2017-02-15 |
2024-10-14 |
Taiho Pharmaceutical Co Ltd |
Farmaceutisk sammensætning
|
|
KR102420892B1
(ko)
*
|
2017-05-26 |
2022-07-14 |
쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 |
요산 배출을 촉진시키는 urat1 억제제
|
|
JP7234201B2
(ja)
*
|
2017-07-12 |
2023-03-07 |
ブリストル－マイヤーズ スクイブ カンパニー |
心不全の治療のためのｒｏｃｋの５員アミノヘテロ環および５，６－または６，６員二環式アミノヘテロ環の阻害剤
|
|
US11225475B2
(en)
|
2017-08-07 |
2022-01-18 |
Alkermes, Inc. |
Substituted pyridines as inhibitors of histone deacetylase
|
|
EP3682882A4
(en)
|
2017-09-08 |
2021-06-02 |
Taiho Pharmaceutical Co., Ltd. |
ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
|
|
CN112135825A
(zh)
|
2018-03-13 |
2020-12-25 |
夏尔人类遗传性治疗公司 |
血浆激肽释放酶抑制剂及其用途
|
|
CN114728962B
(zh)
|
2019-09-18 |
2025-09-19 |
武田药品工业有限公司 |
血浆激肽释放酶抑制剂及其用途
|
|
WO2021055589A1
(en)
|
2019-09-18 |
2021-03-25 |
Shire Human Genetic Therapies, Inc. |
Heteroaryl plasma kallikrein inhibitors
|
|
TR202009388A1
(tr)
*
|
2020-06-17 |
2021-12-21 |
Anadolu Ueniversitesi |
Akci̇ğer kanseri̇ tedavi̇si̇nde hedefe yöneli̇k yeni̇ tri̇azoloti̇yadi̇azi̇n türevleri̇
|
|
TR202010296A1
(tr)
|
2020-06-30 |
2022-01-21 |
Anadolu Ueniversitesi |
Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri
|
|
KR20230153387A
(ko)
|
2021-02-02 |
2023-11-06 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Ｇｐｒ８４アンタゴニストおよびその使用
|
|
US20240199613A1
(en)
*
|
2021-03-17 |
2024-06-20 |
Takeda Pharmaceutical Company Limited |
Polycyclic inhibitors of plasma kallikrein
|